LY2951742, a humanized monoclonal antibody that potently and selectively binds to Calcitonin Gene Related Peptide (CGRP). Arteaus is developing LY2951742 for migraine prevention.

Arteaus antibody LY2951742 is able to neutralize CGRP and block it from binding to its receptor. By stopping CGRP’s effects on nearby tissue, LY2051742 may be able to reduce migraine attacks as well as potentially decrease the severity of their symptoms.